Newborn affected by maternal antineoplastic chemotherapy

This code signifies a newborn who has been adversely affected by the mother's exposure to antineoplastic chemotherapy agents during pregnancy. The newborn may exhibit various signs and symptoms, including congenital malformations, growth restriction, or other toxic effects directly attributable to the maternal chemotherapy. This represents an in-utero exposure with subsequent impact on the neonate.

Apply this code when documentation clearly indicates a newborn's condition or anomaly is a direct consequence of maternal antineoplastic chemotherapy received during gestation. Supporting documentation should include details of the mother's chemotherapy regimen and a physician's assessment linking the newborn's findings to this exposure. This code is typically used as a secondary diagnosis, following the code for the specific condition or anomaly observed in the newborn.

• Always sequence the specific congenital anomaly or condition affecting the newborn first, followed by this code.
• Ensure documentation explicitly states the maternal chemotherapy as the causative agent for the newborn's condition.
• Do not use for newborns affected by other maternal medications; this code is specific to antineoplastic agents.